https://www.selleckchem.com/pr....oducts/salinosporami
PF06821497 has been identified as an orally available small molecule EZH2 inhibitor. The objectives of the present study were to characterize pharmacokinetic-pharmacodynamic-disease relationships of PF06821497 in xenograft mouse models with diffuse large B-cell lymphoma (Karpas422). An indirect response model reasonably fit dose-dependent pharmacodynamic responses (H3K27me3 inhibition) with an unbound EC50 of 76 nM while a signal transduction model sufficiently fit dose-dependent disease responses (tumor gro
Beğen
Yorum Yap
Paylaş
